<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569191</url>
  </required_header>
  <id_info>
    <org_study_id>Allergy12</org_study_id>
    <nct_id>NCT01569191</nct_id>
  </id_info>
  <brief_title>Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis</brief_title>
  <official_title>Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many
      people, caused by hypersensitivity to normally harmless substances such as pollen, and often
      accompanies seasonal hay fever. Treatments that can be used before initiating medical therapy
      include artificial tear supplements (ATS) and cold compresses (CC). However, there is no
      evidence in the scientific literature that demonstrates their efficacy compared to no
      treatment or their combined effect with anti-allergic medication. Therefore the investigators
      aim to examine the efficacy of ATS and CC alone, in comparison to anti-allergic medication,
      and CC in combination with anti-allergic medication. In addition, the investigators also aim
      to determine the time course of ocular allergic reactions. At the end of the study the
      investigators will be able to see whether or not ATS and CC are effective in treating SAC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be a total of 6 study visits, each lasting approximately 1 hour and separated by
      at least 2 days. At the beginning of each visit, a set of measurements will be taken by an
      experienced optometrist. These are:

        -  What symptoms you are feeling and how severe they are - you will be asked to complete a
           short questionnaire about how your eyes currently feel.

        -  The redness and temperature of your eyes - the front surface of both eyes will be
           photographed using digital cameras.

      After these measurements we will ask you to stand inside a specially designed room where the
      environment can be controlled by a computer. The pollen that you were found to be allergic to
      will then be introduced into the atmosphere of the room, so that the signs and symptoms of
      SAC can be induced - this is intentional, but normally resolves within a few hours with no
      treatment. At each visit, you will experience a different duration (no longer than 10
      minutes) and either no treatment, artificial tear supplement (ATS; preservative free ocular
      lubricant), cold compress (CC; cooled gel eye mask) or anti-allergic medication (epinastine
      hydrochloride 500μg/mL). The measurements will then be repeated even 5 minutes for an hour.

      After the final set of measurements, the front surface of your eyes will be assessed using a
      temporary dye to highlight using a blue light any changes. Fluorescein dye does not sting,
      lasts only a few minutes and has no effect on vision or driving. However it may cause a self
      limiting mild allergic reaction where the eyes become red, irritated and sore but this is
      highly unlikely as there are no known reported cases. In the unlikely event this does happen
      the experienced optometrist is immediately available to manage the condition.

      The anti-allergic drug epinastine hydrochloride (Elestat, Allergan) is a prescription only
      medicine indicated for the treatment of allergic conjunctivitis. As with all medications,
      there are potential side effects - although uncommon (1 in 10 to 1 in 100 people), there may
      be a slight burning sensation on application but this temporary and subsides quickly. The
      epinastine formulation also contains preservatives called benzalkonium chloride and disodium
      edetate. As with fluorescein sodium, these may cause a self limiting mild allergic reaction.
      In the unlikely event this does happen the experienced optometrist is immediately available
      to manage the condition.

      Study Length and Reimbursement Each of the 6 measurement visits is separated by 7 days
      therefore the total study length for each participant is 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms</measure>
    <time_frame>1 hour</time_frame>
    <description>Short questionnaire Ocular allergy symptomology was also measured using the eye symptom section from the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) on a 0 to 6 scale, with the summed score for itching, watering, swelling and soreness resulting in a summed score between 0 and 24. A higher score indicates a worse outcome (more severe symptoms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Redness</measure>
    <time_frame>1 hour</time_frame>
    <description>Bulbar and limbal redness will be observed with a slit lamp biomicroscope and graded using a validated scale
• The 'Efron' grading scale consists of 5 pictures of eyes of increasing severity of blood vessels over the white of the eye, with the clinician selecting the image closest to what they observe on the patient (0 indicating a white eye and 4 a very irritated eye). There are no subscales</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Temperature</measure>
    <time_frame>1 hour</time_frame>
    <description>Ocular surface temperature will be measured with an infra-red camera</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Exposure to grass pollen only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial Tear Supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold compress</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-allergic Medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Artificial Tear Supplement</intervention_name>
    <description>artificial tear supplement (Hypromellose)</description>
    <arm_group_label>Artificial Tear Supplement</arm_group_label>
    <other_name>Hypromellose is also sold as Isopto plain eye drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cold compress</intervention_name>
    <description>Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue</description>
    <arm_group_label>Cold compress</arm_group_label>
    <other_name>Eye-gel-mask-blue</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-allergic Medication</intervention_name>
    <description>1 drop on single occasion after exposure to grass pollen</description>
    <arm_group_label>Anti-allergic Medication</arm_group_label>
    <other_name>ELESTAT® (epinastine HCl ophthalmic solution) 0.05%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of seasonal allergic conjunctivitis or seasonal allergic rhinoconjunctivitis
             (seasonal hay fever) that is not currently active.

        Exclusion Criteria:

          -  eye surgery in the last 3 months

          -  active eye condition

          -  adverse reaction to ocular drugs or dyes

          -  history of anaphylaxis (severe systemic allergic reaction)

          -  use any ocular medication or systemic medications (antihistamines, mast cell
             stabilisers, non-steroidal anti-inflammatory drugs or steroids) at least 14 days prior
             to the start and for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Wolffsohn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Pollen and Aerobiology Unit</name>
      <address>
        <city>Worcester</city>
        <zip>WR2 6AJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>April 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2012</study_first_posted>
  <results_first_submitted>June 22, 2015</results_first_submitted>
  <results_first_submitted_qc>July 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2018</results_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ocular allergy</keyword>
  <keyword>Tear supplement</keyword>
  <keyword>Cold compress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Epinastine</mesh_term>
    <mesh_term>Anti-Allergic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>No Treatment/Artificial Tear / Cold Compress / Pharmaceutical</title>
          <description>Exposure to grass pollen only
Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006 Non-Pharmaceutical Tear Supplement artificial tear
Cooled gel eye mask http://www.visiondirect.co.uk/visiondirect/ eye-gel-mask-blue Eye Gel Mask Blue placed over the closed eyes: Bag fill with temperature retention gel
ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist</description>
        </group>
        <group group_id="P2">
          <title>No Treatment / Artificial Tear / Cold Compress</title>
          <description>Exposure to grass pollen only
Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006 Non-Pharmaceutical Tear Supplement artificial tear
Cooled gel eye mask http://www.visiondirect.co.uk/visiondirect/ eye-gel-mask-blue Eye Gel Mask Blue placed over the closed eyes: Bag fill with temperature retention gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects underwent skin prick and bilateral conjunctival challenge tests to confirm systemic and ocular allergic sensitivity to grass pollen</population>
      <group_list>
        <group group_id="B1">
          <title>No Treatment / Artificial Tear / Cold Compress / Pharmaceutica</title>
          <description>Exposure to grass pollen only
Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006 Non-Pharmaceutical Tear Supplement artificial tear
Cooled gel eye mask http://www.visiondirect.co.uk/visiondirect/ eye-gel-mask-blue Eye Gel Mask Blue placed over the closed eyes: Bag fill with temperature retention gel
ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
ELESTAT® (epinastine HCl ophthalmic solution) 0.05%: 1 drop on single occasion after exposure to grass pollen</description>
        </group>
        <group group_id="B2">
          <title>No Treatment / Artificial Tear / Cold Compress</title>
          <description>Exposure to grass pollen only
Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006 Non-Pharmaceutical Tear Supplement artificial tear
Cooled gel eye mask http://www.visiondirect.co.uk/visiondirect/ eye-gel-mask-blue Eye Gel Mask Blue placed over the closed eyes: Bag fill with temperature retention gel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="11.0"/>
                    <measurement group_id="B2" value="29.4" spread="10.7"/>
                    <measurement group_id="B3" value="29.5" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Symptoms</title>
        <description>Short questionnaire Ocular allergy symptomology was also measured using the eye symptom section from the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) on a 0 to 6 scale, with the summed score for itching, watering, swelling and soreness resulting in a summed score between 0 and 24. A higher score indicates a worse outcome (more severe symptoms)</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Exposure to grass pollen only</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tear Supplement</title>
            <description>Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
Non-Pharmaceutical Tear Supplement: artificial tear supplement (Hypromellose)</description>
          </group>
          <group group_id="O3">
            <title>Cold Compress</title>
            <description>Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
Eye Gel Mask Blue placed over the closed eyes: Bag fill with temperature retention gel</description>
          </group>
          <group group_id="O4">
            <title>Anti-allergic Medication</title>
            <description>ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
ELESTAT® (epinastine HCl ophthalmic solution) 0.05%: 1 drop on single occasion after exposure to grass pollen</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms</title>
          <description>Short questionnaire Ocular allergy symptomology was also measured using the eye symptom section from the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) on a 0 to 6 scale, with the summed score for itching, watering, swelling and soreness resulting in a summed score between 0 and 24. A higher score indicates a worse outcome (more severe symptoms)</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="1.8"/>
                    <measurement group_id="O2" value="11.3" spread="1.2"/>
                    <measurement group_id="O3" value="13.3" spread="1.1"/>
                    <measurement group_id="O4" value="9.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Redness</title>
        <description>Bulbar and limbal redness will be observed with a slit lamp biomicroscope and graded using a validated scale
• The 'Efron' grading scale consists of 5 pictures of eyes of increasing severity of blood vessels over the white of the eye, with the clinician selecting the image closest to what they observe on the patient (0 indicating a white eye and 4 a very irritated eye). There are no subscales</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Exposure to grass pollen only</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tear Supplement</title>
            <description>Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
Non-Pharmaceutical Tear Supplement: artificial tear supplement (Hypromellose)</description>
          </group>
          <group group_id="O3">
            <title>Cold Compress</title>
            <description>Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
Eye Gel Mask Blue placed over the closed eyes: Bag fill with temperature retention gel</description>
          </group>
          <group group_id="O4">
            <title>Anti-allergic Medication</title>
            <description>ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
ELESTAT® (epinastine HCl ophthalmic solution) 0.05%: 1 drop on single occasion after exposure to grass pollen</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Redness</title>
          <description>Bulbar and limbal redness will be observed with a slit lamp biomicroscope and graded using a validated scale
• The 'Efron' grading scale consists of 5 pictures of eyes of increasing severity of blood vessels over the white of the eye, with the clinician selecting the image closest to what they observe on the patient (0 indicating a white eye and 4 a very irritated eye). There are no subscales</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="0.40"/>
                    <measurement group_id="O2" value="1.79" spread="0.40"/>
                    <measurement group_id="O3" value="1.61" spread="0.32"/>
                    <measurement group_id="O4" value="1.78" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Temperature</title>
        <description>Ocular surface temperature will be measured with an infra-red camera</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>Exposure to grass pollen only</description>
          </group>
          <group group_id="O2">
            <title>Artificial Tear Supplement</title>
            <description>Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
Non-Pharmaceutical Tear Supplement: artificial tear supplement (Hypromellose)</description>
          </group>
          <group group_id="O3">
            <title>Cold Compress</title>
            <description>Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
Eye Gel Mask Blue placed over the closed eyes: Bag fill with temperature retention gel</description>
          </group>
          <group group_id="O4">
            <title>Anti-allergic Medication</title>
            <description>ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
ELESTAT® (epinastine HCl ophthalmic solution) 0.05%: 1 drop on single occasion after exposure to grass pollen</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Temperature</title>
          <description>Ocular surface temperature will be measured with an infra-red camera</description>
          <units>degrees centrigrade</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.88" spread="0.75"/>
                    <measurement group_id="O2" value="35.91" spread="0.96"/>
                    <measurement group_id="O3" value="35.41" spread="0.88"/>
                    <measurement group_id="O4" value="34.56" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>No Treatment</title>
          <description>Exposure to grass pollen only</description>
        </group>
        <group group_id="E2">
          <title>Artificial Tear Supplement</title>
          <description>Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
Non-Pharmaceutical Tear Supplement: artificial tear supplement (Hypromellose)</description>
        </group>
        <group group_id="E3">
          <title>Cold Compress</title>
          <description>Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
Eye Gel Mask Blue placed over the closed eyes: Bag fill with temperature retention gel</description>
        </group>
        <group group_id="E4">
          <title>Anti-allergic Medication</title>
          <description>ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
ELESTAT® (epinastine HCl ophthalmic solution) 0.05%: 1 drop on single occasion after exposure to grass pollen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof James Wolffsohn</name_or_title>
      <organization>Aston University</organization>
      <phone>+44(0)1212044140</phone>
      <email>j.s.w.wolffsohn@aston.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

